Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227467 | 0.86 | CRBN (0.71) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL25571841 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL21751123 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL3653386 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL3647668 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL30423431 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24717459 | 0.85 | CRBN (0.64) | CRBNDDB1IKZF3 | |
| SCHEMBL21751066 | 0.82 | CRBN (0.66) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL17169744 | 0.82 | CRBN (1.00) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL29923298 | 0.82 | CRBN (1.00) | CRBNDDB1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621664-B | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2023-08-01 | — | — | CN | disclosed |
| EP-3623366-B9 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3623366-B1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-01-19 | — | — | EP | disclosed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| EP-3623366-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| CN-110621664-A | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2019-12-27 | — | — | CN | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-9096573-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2200999-B1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-10-31 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| CN-101952272-A | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2011-01-19 | — | — | CN | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885IKZF3 4761/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885IKZF3 4761/4885 |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 153/4885IKZF3 969/4885 |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 196/4885IKZF3 822/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885IKZF3 4761/4885 |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885IKZF3 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.